Risk factors

Heavy reliance on TraceCop and U.S. government customers creates significant revenue concentration risks. Persistent net losses and accumulated deficits threaten ongoing operations and expansion. Nasdaq listing compliance and stock price volatility pose continuous financial pressures.

Revenue concentration is severe: one customer generated 75.0% of 2024 revenue, up from 60.4% in 2023.

Single-family rental operations depend heavily on local market conditions, rental rate growth, and property operating cost inflation.

Iovance faces substantial accumulated deficits of $2.4 billion and net losses of $372.2 million in 2024 while commercializing its lead product, Amtagvi.

Disc Medicine faces substantial financial losses, having incurred a net loss of $109.4 million in 2024. The company has no approved products for commercial sale and relies entirely on clinical-stage hematologic programs. Operations depend heavily on third-party manufacturers, sole-source API suppliers, and collaborative partnerships like Mabwell and NIH.

Janux is an early-stage biopharmaceutical company with no product revenue, relying entirely on external funding and unproven platform technologies like JANX007 and JANX008.

Koppers Holdings faces significant debt obligations totaling $939.5 million alongside substantial environmental and chemical manufacturing hazards.

Kimbell Royalty Partners relies entirely on oil and natural gas mineral interests, exposing it to commodity price volatility and third-party operator risks. Distributions depend on variable cash flow rather than net income, constrained by high debt leverage and acquisition growth needs. The company operates as a master limited partnership with governance structures heavily favoring the general partner and sponsors.

Kymera faces intense risks from its unproven targeted protein degradation platform and heavy reliance on early-stage pipeline success. The company requires ongoing capital raises and depends on limited third-party suppliers for drug materials. Extensive regulation, pricing controls, and clinical trial execution heavily impact future viability.

LifeStance Health's risks are dominated by third-party payor dependence, clinician retention and recruitment, and complex healthcare regulations.

LENSAR faces continuing operating losses with a $143.3 million accumulated deficit as of December 31, 2024.

LeonaBio is a clinical-stage biopharmaceutical company focused on neurodegeneration, dealing with the clinical development of ATH-1105 after halting fosgonimeton due to failed Phase 2/3 trial results.